LIFE News and Press, aTyr Pharma Inc. From 01/18/23

European Commission (EC) granted orphan drug designation to aTyr Pharma's ( NASDAQ: LIFE ) efzofitimod to treat sarcoidosis. Sarcoidosis is a disorder characterized by the growth of tiny collections of inflammatory cells (granulomas) in any body part, commonly the lungs and lymph ...

SAN DIEGO, Jan. 18, 2023 (GLOBE NEWSWIRE) --  aTyr Pharma, Inc. (Nasdaq: LIFE), a biotherapeutics company engaged in the discovery and development of first-in-class medicines from its proprietary tRNA synthetase platform, today announced that the European Commission (EC) granted orphan drug ...

LTBP1 is key regulator of TGF-β, a major driver of fibrosis. Latest target identified from company’s platform in collaboration with Dualsystems Biotech AG. SAN DIEGO, Dec. 15, 2022 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: LIFE), a biotherapeutics company engage...

aTyr Pharma, Inc. (LIFE) Q3 2022 Earnings Conference Call November 10, 2022 05:00 PM ET Company Participants Ashlee Dunston - Director, IR & Corporate Communications Sanjay Shukla - President & CEO Jill Broadfoot - CFO Conference Call Participants ...

aTyr Pharma press release ( NASDAQ: LIFE ): Q3 GAAP EPS of -$0.46 in-line. Cash, restricted cash, cash equivalents and investments as of September 30, 2022, were $79.6 million For further details see: aTyr Pharma GAAP EPS of -$0.46 in-line

First patient dosed in Phase 3 EFZO-FIT™ study in patients with pulmonary sarcoidosis; multiple centers in the U.S. are open for enrollment. Company to prioritize resources towards largest value driver efzofitimod program. Ended the third quarter 2022 with $79.6 m...

SAN DIEGO, Nov. 10, 2022 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: LIFE), a biotherapeutics company engaged in the discovery and development of first-in-class medicines from its proprietary tRNA synthetase platform, today announced that Sanjay S. Shukla, M.D., M.S., President and Chief...

First therapy in sarcoidosis to reduce steroid burden while demonstrating improvements in key physiologic and quality of life measures. Global pivotal Phase 3 EFZO-FIT™ study currently enrolling. SAN DIEGO, Nov. 09, 2022 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq...

SAN DIEGO, Nov. 03, 2022 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: LIFE), a biotherapeutics company engaged in the discovery and development of first-in-class medicines from its proprietary tRNA synthetase biology platform, today announced that it will report third quarter 2022 financi...

SAN DIEGO, Oct. 25, 2022 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: LIFE), a biotherapeutics company engaged in the discovery and development of first-in-class medicines from its proprietary tRNA synthetase platform, today announced that Sanjay S. Shukla, M.D., M.S., President and Chief...